Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study

Keyphrases

• 5-fluorouracil (5-FU) 100%
• Bladder Cancer 10%
• Breast Cancer Treatment 10%
• Chemotherapy Agents 10%
• Cholangiocarcinoma 10%
• Cytidine Triphosphate 10%
• Disease Progression 10%
• DNA Synthesis 10%
• Drug Sequencing 10%
• ECOG Performance Status 10%
• Eligibility Requirements 10%
• First Cycle 10%
• Fluorouracil 20%
• Gemcitabine 100%
• Hematologic 10%
• Hepatic Functional Reserve 10%
• In Tandem 10%
• Informed Consent 10%
• Leucovorin 100%
• Lung Cancer Treatment 10%
• Maximum Tolerated Dose 10%
• Number of Cycles 10%
• Pancreas Cancer 10%
• Partial Response 10%
• Performance Status 10%
• Phase I Study 100%
• Phase I Trial 10%
• Prior Chemotherapy 10%
• Refractory Solid Tumors 10%
• Renal Functional Reserve 10%
• Ribonucleotide Reductase 10%
• Sequence-dependent 10%
• Starting Dose 20%
• Thymidylate Synthase 10%
• Tumor Malignancy 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Bile Duct Carcinoma 10%
• Bladder Cancer 10%
• Breast Cancer 10%
• Chemotherapy Agent 10%
• Cytidine Triphosphate 10%
• Disease Exacerbation 10%
• Fluorouracil 100%
• Folinic Acid 100%
• Gemcitabine 100%
• Lung Cancer 10%
• Maximum Tolerated Dose 10%
• Pancreas Cancer 10%
• Patient History of Chemotherapy 10%
• Phase I Trials 10%
• Ribonucleotide Reductase 10%
• Solid Malignant Neoplasm 10%
• Thymidylate Synthase 10%